The Goeckerman Regimen as an Effective Treatment Modality for Checkpoint Inhibitor Dermatoses
Main Article Content
Keywords
Goeckerman regimen, checkpoint inhibitor dermatosis, bullous pemphigoid, psoriasiform dermatitis, cytotoxic dermatitis, goeckerman regimen, checkpoint inhibitor, bullous, psorasiform dermatitis, cytotoxic dermatitis
Abstract
The development of immune checkpoint inhibitors has been a major breakthrough in cancer therapy. Here, we report the effective use of the Goeckerman regimen in the treatment of an evolving immune checkpoint inhibitor dermatosis. The patient is a 67-year-old male who was diagnosed with mesothelioma in April 2015 and was started on pembrolizumab presenting with subsequent skin eruptions (psoriasiform dermatitis and bullous disease). He received eight months of Goeckerman therapy at University of California, San Francisco, Psoriasis and Skin Treatment Center. Within days of starting Goeckerman therapy, he had rapid improvement in his skin lesions along with a reduction in pruritus. The Goeckerman regimen is further discussed as a novel treatment method for checkpoint inhibitor dermatoses.
References
2. Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma. JAMA Dermatol. 2016;152(5):590-592. doi:10.1001/jamadermatol.2015.5210
3. Gupta R, Debbaneh M, Butler D, et al. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. J Vis Exp. 2013;(77). doi:10.3791/50509
4. Crow LD, Perkins I, Twigg AR, et al. Treatment of PD-1/PD-L1 Inhibitor–Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas. JAMA Dermatol. 2020;156(5):598-600. doi:10.1001/jamadermatol.2020.0176
5. Albergo RP, Gilgor RS. Delayed onset of bullous pemphigoid after PUVA and sunlight treatment of psoriasis. Cutis. 1982;30(5):621-624.
6. Suwarsa O, Herlina L, Sutedja E, Dharmadji H, Hindritiani R, Gunawan H. Concurrence of Bullous Pemphigoid and Psoriasis: A Case Report. Serbian Journal of Dermatology and Venereology. 2018;10:124-128. doi:10.2478/sjdv-2018-0018
7. Zhang X, Mao X, Theresia C, et al. Pemphigus Associated with Psoriasis Vulgaris: A Retrospective Study of Seven Patients and a Review of the Literature. Acta Dermatovenerol Croat. 2018;26(3):226-232.
8. Person JR, Rogers RS. Bullous pemphigoid and psoriasis: does subclinical bullous pemphigoid exist? Br J Dermatol. 1976;95(5):535-540. doi:10.1111/j.1365-2133.1976.tb00865.x
9. Robinson JK, Baughman RD, Provost TT. Bullous pemphigoid induced by PUVA therapy. Is this the aetiology of the acral bullae produced during PUVA treatment? Br J Dermatol. 1978;99(6):709-713. doi:10.1111/j.1365-2133.1978.tb07067.x
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.